Clinical Research Directory
Browse clinical research sites, groups, and studies.
Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure
Sponsor: Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Summary
The objective of the study is to compare short-term (8 weeks) anticoagulation therapy (DOAC) vs. antiplatelet therapy for the prevention of device thrombosis following transcatheter LAAC.
Official title: Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure. The ANDES Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
510
Start Date
2018-09-01
Completion Date
2030-09-01
Last Updated
2026-03-27
Healthy Volunteers
Yes
Interventions
Rivaroxaban, dabigatran, apixaban, or edoxaban
Duration of treatment: 60 days
Clopidogrel -75 mg/day
Duration of treatment: 60 days
Low dose aspirin -80 to 125 mg/day-
Duration of treatment: 60 days
Locations (1)
Josep Rodes-Cabau
Québec, Quebec, Canada